Your browser doesn't support javascript.
loading
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry.
Balbi, Gustavo G M; Ahmadzadeh, Yasaman; Tektonidou, Maria G; Pengo, Vittorio; Sciascia, Savino; Ugarte, Amaia; Belmont, H Michael; Lopez-Pedrera, Chary; Fortin, Paul R; Wahl, Denis; Gerosa, Maria; de Jesús, Guilherme R; Ji, Lanlan; Atsumi, Tatsuya; Efthymiou, Maria; Branch, D Ware; Nalli, Cecilia; Rodriguez Almaraz, Esther; Petri, Michelle; Cervera, Ricard; Knight, Jason S; Artim-Esen, Bahar; Willis, Rohan; Bertolaccini, Maria Laura; Cohen, Hannah; Roubey, Robert; Erkan, Doruk; de Andrade, Danieli Castro Oliveira.
Afiliação
  • Balbi GGM; Universidade de São Paulo, São Paulo, São Paulo, Brazil.
  • Ahmadzadeh Y; Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
  • Tektonidou MG; Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA.
  • Pengo V; National and Kapodistrian University of Athens, Athens, Greece.
  • Sciascia S; University Hospital Padova, Padova, Italy.
  • Ugarte A; Center of Research of Immunopathology and Rare Diseases, University of Turin, Turin, Italy.
  • Belmont HM; Hospital Universitario Cruces, País Vasco, Barakaldo, Spain.
  • Lopez-Pedrera C; Hospital for Joint Diseases, New York University, New York, NY, USA.
  • Fortin PR; Rheumatology Service, IMIBIC/Reina Sofia Hospital, University of Cordoba, Cordoba, Spain.
  • Wahl D; CHU de Québec-Université Laval, Québec, Québec, Canada.
  • Gerosa M; Université de Lorraine, INSERM, DCAC, Nancy, France.
  • de Jesús GR; Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU-Nancy, Nancy, France.
  • Ji L; Clinical Immunology & Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • Atsumi T; Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Efthymiou M; Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China.
  • Branch DW; Hokkaido University Hospital, Sapporo, Japan.
  • Nalli C; Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
  • Rodriguez Almaraz E; University of Utah and Intermountain Healthcare, Salt Lake City, UT, USA.
  • Petri M; Rheumatology and Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Italy.
  • Cervera R; Hospital Universitario, 12 de Octubre, Madrid, Spain.
  • Knight JS; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Artim-Esen B; Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain.
  • Willis R; Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.
  • Bertolaccini ML; Istanbul University School of Medicine, Istanbul, Turkey.
  • Cohen H; Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
  • Roubey R; Academic Department of Vascular Surgery, King's College London British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine & Sciences, London, UK.
  • Erkan D; Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
  • de Andrade DCO; University of North Carolina, Chapel Hill, NC, USA.
Rheumatology (Oxford) ; 63(3): 772-779, 2024 Mar 01.
Article em En | MEDLINE | ID: mdl-37307082
OBJECTIVES: Our primary objective was to quantify damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis in an international cohort (the APS ACTION cohort). Secondly, we aimed to identify clinical and laboratory characteristics associated with damage in aPL-positive patients. METHODS: In this cross-sectional study, we analysed the baseline damage in aPL-positive patients with or without APS classification. We excluded patients with other autoimmune diseases. We analysed the demographic, clinical and laboratory characteristics based on two subgroups: (i) thrombotic APS patients with high vs low damage; and (ii) non-thrombotic aPL-positive patients with vs without damage. RESULTS: Of the 826 aPL-positive patients included in the registry as of April 2020, 586 with no other systemic autoimmune diseases were included in the analysis (412 thrombotic and 174 non-thrombotic). In the thrombotic group, hyperlipidaemia (odds ratio [OR] 1.82; 95% CI 1.05, 3.15; adjusted P = 0.032), obesity (OR 2.14; 95% CI 1.23, 3.71; adjusted P = 0.007), aß2GPI high titres (OR 2.33; 95% CI 1.36, 4.02; adjusted P = 0.002) and corticosteroid use (ever) (OR 3.73; 95% CI 1.80, 7.75; adjusted P < 0.001) were independently associated with high damage at baseline. In the non-thrombotic group, hypertension (OR 4.55; 95% CI 1.82, 11.35; adjusted P = 0.001) and hyperlipidaemia (OR 4.32; 95% CI 1.37, 13.65; adjusted P = 0.013) were independent predictors of damage at baseline; conversely, single aPL positivity was inversely correlated with damage (OR 0.24; 95% CI 0.075, 0.77; adjusted P = 0.016). CONCLUSIONS: DIAPS indicates substantial damage in aPL-positive patients in the APS ACTION cohort. Selected traditional cardiovascular risk factors, steroids use and specific aPL profiles may help to identify patients more prone to present with a higher damage burden.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome Antifosfolipídica / Hiperlipidemias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome Antifosfolipídica / Hiperlipidemias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido